CLINICAL RESPONSE TO ANTINEOPLASTICS (AZATHIOPRINE, CAPECITABINE, FLUOROURACIL, IRINOTECAN, METHOTREXATE, TAMOXIFEN): CLINICAL EXOME PANEL (Sec. & CNVs) – 7 genes

The Clinical Response to Antineoplastic Agents panel focuses on analyzing genetic variants that influence the efficacy, toxicity, and metabolism of the main drugs used in chemotherapy and hormone therapy for cancer. Certain polymorphisms can increase susceptibility to serious adverse reactions or reduce therapeutic response, making them key to optimizing treatment. The study includes the DPYD gene, involved in the degradation of fluorouracil and capecitabine, whose deficiency can cause severe toxicity; TPMT and NUDT15, essential in the metabolism of azathioprine and 6-mercaptopurine; UGT1A1, which modulates irinotecan detoxification; CYP2D6, responsible for tamoxifen activation; and MTHFR and SLC19A1, related to the response to and adverse effects of methotrexate. This analysis allows for individualized dosing, prevention of serious hematological or gastrointestinal complications, and maximization of therapeutic efficacy in precision oncology. Key genes analyzed: DPYD, TPMT, NUDT15, UGT1A1, CYP2D6, MTHFR and SLC19A1.